Abstract
Intestinal ultrasound is a noninvasive, cost-effective tool to assess disease activity in ulcerative colitis (UC). Although upadacitinib, a selective Janus kinase 1 inhibitor, has demonstrated efficacy for induction therapy in patients with moderately to severely active UC, data in acute severe UC remain limited. We report on the use of intestinal ultrasound to assess treatment response after induction with upadacitinib in 3 patients hospitalized with acute severe UC.